Key result
Claudication medical therapy prioritizes cardiovascular risk reduction and pharmacotherapy to improve walking symptoms.
Answers are grounded in this paper and cite their sources.
The symptoms of intermittent claudication (IC) lead sufferers to seek medical attention, potentially leading to substantial workup and invasive testing. However, only a minority of people with IC develop limb-threatening ischemia or symptoms of significant lifestyle-limiting claudication. Patients with IC have a substantial risk of concomitant cardiovascular and cerebrovascular disease. Assessment of co-morbidities and control of risk factors reduce the cardiovascular risk of these patients. A multitude of drugs have been developed and tested in numerous trials for the symptoms of IC. Although no drug alone offers a "cure" to IC, some are used as adjuvant therapy to reduce claudication symptoms.
No takes yet. Share an insight, caveat, or question.
Casey et al. (2004) conducted a review in Intermittent claudication. Medical management and pharmacotherapy was evaluated. Medical management of intermittent claudication focuses on controlling cardiovascular risk factors and using adjuvant pharmacotherapy to reduce claudication symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: